CureVac NV (CureVac NV) Days Inventory : 40.52 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). CureVac NV's Average Total Inventories for the three months ended in Dec. 2023 was $25.96 Mil. CureVac NV's Cost of Goods Sold for the three months ended in Dec. 2023 was $58.45 Mil. Hence, CureVac NV's Days Inventory for the three months ended in Dec. 2023 was 40.52.

The historical rank and industry rank for CureVac NV's Days Inventory or its related term are showing as below:

CVAC' s Days Inventory Range Over the Past 10 Years
Min: 55.01 Med: 65.65 Max: 260
Current: 69.38

During the past 6 years, CureVac NV's highest Days Inventory was 260.00. The lowest was 55.01. And the median was 65.65.

CVAC's Days Inventory is ranked better than
81.87% of 651 companies
in the Biotechnology industry
Industry Median: 189.69 vs CVAC: 69.38

CureVac NV's Days Inventory increased from Dec. 2022 (17.88) to Dec. 2023 (40.52). It might indicate that CureVac NV's sales slowed down.

Inventory Turnover measures how fast the company turns over its inventory within a year. CureVac NV's Inventory Turnover for the three months ended in Dec. 2023 was 2.25.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. CureVac NV's Inventory-to-Revenue for the three months ended in Dec. 2023 was 1.05.

CureVac NV Days Inventory Historical Data

The historical data trend for CureVac NV's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Days Inventory Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Inventory

Get a 7-Day Free Trial

60.12

260.00

55.01

83.21

70.59

CureVac NV Quarterly Data
	Dec18	Mar19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Inventory	Get a 7-Day Free Trial															17.88	107.04	82.20	86.12	40.52

Competitive Comparison of CureVac NV's Days Inventory

For the Biotechnology subindustry, CureVac NV's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CureVac NV's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CureVac NV's Days Inventory distribution charts can be found below:

* The bar in red indicates where CureVac NV's Days Inventory falls into.

CureVac NV Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

CureVac NV's Days Inventory for the fiscal year that ended in Dec. 2023 is calculated as

	Days Inventory (A: Dec. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (25.412	+	27.046)	/	2 )	/	135.623	*	365
=	26.229					/	135.623	*	365
=	70.59

CureVac NV's Days Inventory for the quarter that ended in Dec. 2023 is calculated as:

	Days Inventory (Q: Dec. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Sep. 2023 )	+	Total Inventories (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (24.867	+	27.046)	/	2 )	/	58.449	*	365 / 4
=	25.9565					/	58.449	*	365 / 4
=	40.52

CureVac NV (NAS:CVAC) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

CureVac NV's Inventory Turnover for the three months ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	58.449	/	25.9565
	=	2.25

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

CureVac NV's Inventory to Revenue for the three months ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	25.9565	/	24.61
	=	1.05

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

CureVac NV Days Inventory Related Terms

Thank you for viewing the detailed overview of CureVac NV's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV (CureVac NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (NAS:CVAC) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

CVAC:Mexico 1CVAC:Italy 0A9E:UK 5CV:Germany CVAC:Austria

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.